RecruitingNot ApplicableNCT07233434

Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe

Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe: a Pilot Study


Sponsor

Centre Hospitalier Universitaire de la Guadeloupe

Enrollment

120 participants

Start Date

Feb 2, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

In France, only the fasting blood glucose (FBG) measurement is recommended for diabetes screening. Ethnic heterogeneity and genetic polymorphisms specific to the Afro-Caribbean and Indo-Caribbean population in Guadeloupe justify the interest to early screen type 2 diabetes mellitus (T2DM). Our main objective is to estimate the prevalence of T2DM defined by oral glucose tolerance (OGTT) in subjects with risk factors for T2DM and not diagnosed with the FBG.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study in Guadeloupe is investigating whether a more comprehensive blood sugar test (oral glucose tolerance test) can identify type 2 diabetes in people of African or Indian descent whose standard fasting blood sugar test comes back normal but who have pre-diabetes markers. **You may be eligible if...** - You are between 18 and 65 years old - You are of African or Indian origin - Your fasting blood glucose is normal but your HbA1c (a 3-month blood sugar average) is between 5.7% and 6.4% (pre-diabetes range) - You have at least one risk factor: BMI over 25, family history of type 2 diabetes, high blood pressure, or abnormal cholesterol - You have social health insurance coverage in France **You may NOT be eligible if...** - You are pregnant or breastfeeding, or have a history of gestational diabetes - You have polycystic ovary syndrome - You have a hormonal, liver, or kidney condition affecting blood sugar - You take medications that affect glucose metabolism Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTAfter inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A contr

After inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A control of the HbA1c levels will be also performed associated with a physical examination.


Locations(1)

Centre Hospitalier Universitaire de la Guadeloupe

Pointe-à-Pitre, Guadeloupe, Guadeloupe

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07233434


Related Trials